

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptal644axd
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 Expanded Caplus Coverage of US, Japanese, WIPO,
EPO, and German patents
NEWS 3 Jan 18 ESBIODBASE - NEW FREE DISPLAY FORMATS, TRIAL
FORMAT ENHANCED
NEWS 4 Feb 1 Addition of Machine-Translated Abstracts to Caplus
NEWS 5 Feb 2 STEREO BOND SEARCH PROBLEM FIXED WITH STN EXPRESS 5.0C
NEWS 6 Feb 14 Homology Searching for Nucleotide Sequences in DGENE
now available!
NEWS 7 Feb 16 BIOTECHNOBASE NOW ON STN
NEWS 8 Feb 22 New Database Producer Clusters Now Available on STN
NEWS 9 Feb 28 Structure Search Limits Increased in REGISTRY,
ZREGISTRY, and CASREACT
NEWS 10 Feb 28 Patent Information Now Searchable in CAOLD
NEWS 11 Mar 1 New IMSDIRECTORY Provides Pharma Company Details

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:19:38 ON 09 MAR 2000

=> file patents medline caplus biosis embase

FILE 'APIPAT2' ACCESS NOT AUTHORIZED
FILE 'PAPERCHEM' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.15	0.15

FILE 'CAPLUS' ENTERED AT 09:19:59 ON 09 MAR 2000 -
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'APIPAT' ENTERED AT 09:19:59 ON 09 MAR 2000
Abstracts copyright (C) Derwent Information Ltd.
Remainder of the file copyright (C) 2000 Elsevier Engineering
Information, Inc. (DERWENT/ELSEVIER)

FILE 'CROPU' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'DGENE' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'DPCI' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'EUROPATFULL' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'IFIPAT' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 IFI CLAIMS(R) Patent Services (IFI)

FILE 'INPADOC' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 European Patent Office, Vienna (EPO)

FILE 'JAPIO' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

FILE 'PAPERCHEM2' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 Institute of Paper Science and Technology (IPST)

FILE 'PATDD' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT 2000 (C) Deutsches Patent- und Markenamt (DPMA)

FILE 'PATDPA' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (c) 2000 Deutsches Patent- und Markenamt / FIZ Karlsruhe (DPMA/FIZ
KA)

FILE 'PATOSDE' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'PATOSEP' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'PATOSWO' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (c) 2000 WILA Verlag Muenchen (WILA)

FILE 'PIRA' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 Pira International

FILE 'RAPRA' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 RAPRA Technology Ltd.

FILE 'TULSA' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 The University of Tulsa (UTULSA)

FILE 'TULSA2' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 The University of Tulsa (UTULSA)

FILE 'USPATFULL' ENTERED AT 09:19:59 ON 09 MAR 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'MEDLINE' ENTERED AT 09:19:59 ON 09 MAR 2000

FILE 'BIOSIS' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 09:19:59 ON 09 MAR 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

=> s HF (1N) COLL (1N)18?

TERM '18?' EXCEEDED TRUNCATION LIMITS - SEARCH ENDED
COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s HF (1N) COLL? or HF?COLL?18?514cf

'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'
'?' TRUNCATION SYMBOL NOT VALID WITHIN 'HF?COLL?18?514CF'

The truncation symbol ? may be used only at the end of a search
term. To specify a variable character within a word use '!', e.g.,
'wom!n' to search for both 'woman' and 'women'. Enter "HELP
TRUNCATION" at an arrow prompt (=>) for more information.

=> s HF (1N) COLL? or HFCOLL?

6 FILES SEARCHED...
15 FILES SEARCHED...
L1 247 HF (1N) COLL? OR HFCOLL?

=> dis l1 (P) fragment

'(P)' IS NOT A VALID FORMAT

'FRAGMENT' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> s l1 (P) fragment

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'L2 (P) FRAGMENT'
15 FILES SEARCHED...
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L17 (P) FRAGMENT'
L2 12 L1 (P) FRAGMENT

=> duplicate remove l2 1-12

DUPLICATE IS NOT AVAILABLE IN 'DGENE, DPCI'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
'1-12' IS NOT VALID. VALID FILE NAMES ARE 'CAPLUS, DGENE, EUROPATFULL,
INPADOC, PATOSEP, PATOSWO, USPATFULL'
You have entered a file name of duplicates to keep that is not
referenced by any of the L#s specified for this DUPLICATE command.
The file names of duplicates that can be kept are listed above.
Please enter one of these file names.
ENTER FILE NAMES OF DUPLICATES TO KEEP:end

=> duplicate remove l2

DUPLICATE IS NOT AVAILABLE IN 'DGENE, DPCI'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'CAPLUS, DGENE, EUROPATFULL, INPADOC, PATOSEP,
PATOSWO, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L2
L3 10 DUPLICATE REMOVE L2 (2 DUPLICATES REMOVED)

=> dis l3 1-10 kwic

L3 ANSWER 1 OF 10 INPADOC COPYRIGHT 2000 EPO
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS

L3 ANSWER 2 OF 10 INPADOC COPYRIGHT 2000 EPO
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS

TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2000 ACS

TI **Collagen fragment HF-COLL-18/514cf**
from body fluids for influencing cell growth and diagnosis of collagen
diseases and osteoporosis

AB **Collagen fragment HF-COLL**
-18/514cf, with the N-terminal sequence Val-Ala-Arg-Asn-Ser-Pro-Leu-Ser-
Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-
Ala-Val-Gly-Leu, was obtained from human hemofiltrate and purified by
cation-exchange chromatog. and preparative reversed-phase chromatog. on a
PrepPak cartridge. The **fragment** (mol. wt. 18,493) or antibodies
to it are useful for treatment or diagnosis of connective tissue,
respiratory, urogenital, circulatory, nervous, . . .

IT Antiosteoporotic agents
Cardiovascular diseases
Connective tissue diseases
Immunoassay
Immunodiagnosis
Infusions (drug delivery systems)
Nervous system diseases

Protein sequences
 Respiratory tract diseases
 Skin diseases
 Tooth diseases
 (collagen fragment HF-COLL
 -18/514cf from body fluids for influencing cell growth and diagnosis
 of
 collagen diseases and osteoporosis)
 IT Antibodies
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (collagen fragment HF-COLL
 -18/514cf from body fluids for influencing cell growth and diagnosis
 of
 collagen diseases and osteoporosis)
 IT Blood proteins
 RL: BAC (Biological activity or effector, except adverse); BPR
 (Biological
 process); PRP (Properties); PUR (Purification or recovery); SPN
 (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); PROC (Process); USES (Uses)
 (collagen fragment HF-COLL
 -18/514cf; collagen fragment HF-
 COLL-18/514cf from body fluids for influencing cell growth and
 diagnosis of collagen diseases and osteoporosis)
 IT Urogenital tract
 (diseases; collagen fragment HF-
 COLL-18/514cf from body fluids for influencing cell growth and
 diagnosis of collagen diseases and osteoporosis)
 IT Genes (animal)
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (for collagen fragment HF-COLL
 -18/514cf of human, expression of; collagen fragment
 HF-COLL-18/514cf from body fluids for influencing
 cell growth and diagnosis of collagen diseases and osteoporosis)
 IT Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of collagen fragment HF-COLL
 -18/514cf; collagen fragment HF-
 COLL-18/514cf from body fluids for influencing cell growth and
 diagnosis of collagen diseases and osteoporosis)
 IT Organ (animal)
 (sensory, diseases; collagen fragment HF-
 COLL-18/514cf from body fluids for influencing cell growth and
 diagnosis of collagen diseases and osteoporosis)
 IT 198403-05-3P
 RL: BAC (Biological activity or effector, except adverse); BPR
 (Biological
 process); PRP (Properties); PUR (Purification or recovery); SPN
 (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); PROC (Process); USES (Uses)
 (collagen fragment HF-COLL
 -18/514cf from body fluids for influencing cell growth and diagnosis
 of
 collagen diseases and osteoporosis)

 L3 ANSWER 4 OF 10 EUROPATFULL COPYRIGHT 2000 WILA
 DETDEN Fibroblasts were released from dermal **fragments** by digesting
 these with Clostridium histolyticum **collagenase**. **HF**s
 were then grown in DMEM using standard methods.

 L3 ANSWER 5 OF 10 INPADOC COPYRIGHT 2000 EPO

TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS

L3 ANSWER 6 OF 10 USPATFULL
DETD Fibroblasts were released from dermal **fragments** by digesting
these with Clostridium histolyticum **collagenase**. **HFs**
were then grown in DMEM using standard methods.

L3 ANSWER 7 OF 10 USPATFULL
DETD Fibroblasts were released from dermal **fragments** by digesting
these with Clostridium histolyticum **collagenase**. **HFs**
were then grown in DMEM using standard methods.

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS
AB . . . (8 keV) collision-induced dissocn. (CID) expts. performed with a
double-focusing quadrupole hybrid mass spectrometer. The 2-fluoro- and
3-fluorophenyl anions eliminate **HF** following **collision**
with an oxygen mol. By contrast, the collisions between 4-fluorophenyl
anions and O2 to not yield detectable amts. of neg. charged
fragment ions owing to the exclusive occurrence of electron
detachment. Electron detachment is also the only process obsd. in the 8.

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2000 ACS
AB . . . 34 kcal/mol at a rather stretched nuclear geometry, is in qual.
agreement with an ab initio surface for the analogous **collinear**
Be + **HF** system. Reaction pathways and reactant-to-product
correlation diagrams are also discussed. A simple estn. of the
sensitivity of the most prominent features of the calcd. potential energy
surfaces to the input diat. **fragment** data demonstrates that
these features cannot be attributed to errors made in those data.

L3 ANSWER 10 OF 10 DGENE COPYRIGHT 2000 DERWENT INFORMATION LTD
AB This is the the N-terminal amino acid sequence of a novel protein
HF-COLL-18/514cf. Medicaments containing **HF-**
COLL-18/514cf or its derivatives or **fragments** are
useful for treating human diseases, especially involving supporting or
connective tissue, the respiratory or urogenital tract, the
cardiovascular or. . . the integuments or the sense organs. The
medicaments are also used for treating systemic diseases with
overproduction or deficiency of **HF-COLL-18/514cf**,
especially with e.g. use of antibodies raised against this or **HF**
-COLL-18/514cf for substitution therapy. The protein, in a
suitable form, can also be used to treat chronic diseases involving
electrolyte action. . . or at the dental apparatus. The protein is
also used for diagnosis of diseases by producing specific antibodies
against synthetic **fragments** or the entire peptide or its
derivatives and its **fragments** and measuring the blood
concentration of **HF-COLL-18/514cf** via an immunoassay

=> dis 13 1-10

L3 ANSWER 1 OF 10 INPADOC COPYRIGHT 2000 EPO DUPLICATE 1

LEVEL 1
AN 27248995 INPADOC EW 199907 UP 19991124 UW 199946
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS
IN FORSSMANN, WOLF-GEORG, PROF.DR.MED.; SCHRADER, MICHAEL; STAENDKER,
LUDGER; RAIDA, MANFRED; SCHULZ-KNAPPE, PETER
INS FORSSMANN WOLF-GEORG PROF DR M; SCHRADER MICHAEL; STAENDKER LUDGER;
RAIDA

MANFRED; SCHULZ-KNAPPE PETER
INA DE; DE; DE; DE; DE
PA HAEMOPEP PHARMA GMBH; BIOVISION GMBH & CO. KG
PAS HAEMOPEP PHARMA GMBH; FORSSMANN WOLF GEORG
PAA DE; DE
TL English; French; German
LA German
DT Patent
PIT EPA2 PUBL. OF APPLICATION WITHOUT SEARCH REPORT
PI EP 896584 A2 19990217
DS R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
AI EP 1997-921682 A 19970422
PRAI DE 1996-19615710 A 19960422
WO 1997-EP2012 W 19970422

L3 ANSWER 2 OF 10 INPADOC COPYRIGHT 2000 EPO DUPLICATE 2

LEVEL 1

AN 42485223 INPADOC UW 199805
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS
IN FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL; STAENDKER, LUDGER; RAIDA,
MANFRED; SCHULZ-KNAPPE, PETER
INS FORSSMANN WOLF-GEORG; SCHRADER MICHAEL; STAENDKER LUDGER; RAIDA MANFRED;
SCHULZ-KNAPPE PETER
INA DE; DE; DE; DE; DE
PA HAEMOPEP PHARMA GMBH; FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL;
STAENDKER, LUDGER; RAIDA, MANFRED; SCHULZ-KNAPPE, PETER
PAS HAEMOPEP PHARMA GMBH; FORSSMANN WOLF GEORG; SCHRADER MICHAEL; STAENDKER
LUDGER; RAIDA MANFRED; SCHULZ Knappe PETER
PAA DE; DE; DE; DE; DE; DE
TL English; French; German
LA German
DT Patent
PIT WOA2 PUBL. OF THE INT. APPL. WITHOUT INT. SEARCH REP.
PI WO 9740073 A2 19971030
DS RW: GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
W: AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KG KP KR LC LK LR
LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY
KG KZ MD RU TJ TM
AI WO 1997-EP2012 A 19970422
PRAI DE 1996-19615710 A 19960422

LEVEL 2

AN 42485223 INPADOC EW 199804 UW 199804
TI BIOLOGICALLY ACTIVE PROTEIN (**COLLAGEN FRAGMENT**
HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS
AND CAPILLARY PROFILERATIONS
IN FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL; STAENDKER, LUDGER; RAIDA,
MANFRED; SCHULZ-KNAPPE, PETER
INS FORSSMANN WOLF-GEORG; SCHRADER MICHAEL; STAENDKER LUDGER; RAIDA MANFRED;
SCHULZ-KNAPPE PETER
INA DE; DE; DE; DE; DE
PA HAEMOPEP PHARMA GMBH; FORSSMANN, WOLF-GEORG; SCHRADER, MICHAEL;
STAENDKER, LUDGER; RAIDA, MANFRED; SCHULZ-KNAPPE, PETER
PAS HAEMOPEP PHARMA GMBH; FORSSMANN WOLF GEORG; SCHRADER MICHAEL; STAENDKER
LUDGER; RAIDA MANFRED; SCHULZ Knappe PETER
PAA DE; DE; DE; DE; DE; DE
TL English; French; German
LA German
DT Patent
PIT WOA3 SUBSEQUENT PUBL. OF THE INT. SEARCH REPORT
PI WO 9740073 A3 19971224

DS RW: GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
W: AL AU BA BB BG BR CA CN CU CZ EE GE GH HU IL IS JP KG KP KR LC LK LR
LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY
KG KZ MD RU TJ TM
AI WO 1997-EP2012 A 19970422
PRAI DE 1996-19615710 A 19960422

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2000 ACS

AN 1997:711835 CAPLUS

DN 127:351169

TI **Collagen fragment HF-COLL-18/514cf**

from body fluids for influencing cell growth and diagnosis of collagen diseases and osteoporosis

IN Schrader, Michael; Forssmann, Wolf-Georg; Raida, Manfred; Schulz-Knappe, Peter

PA Forssmann, Wolf-Georg, Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19615710	A1	19971023	DE 1996-19615710	19960422
	WO 9740073	A2	19971030	WO 1997-EP2012	19970422
	WO 9740073	A3	19971224		

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9727665 A1 19971112 AU 1997-27665 19970422

EP 896584 A2 19990217 EP 1997-921682 19970422

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRAI DE 1996-19615710 19960422

WO 1997-EP2012 19970422

L3 ANSWER 4 OF 10 EUROPATFULL COPYRIGHT 2000 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 526550 EUROPATFULL ED 19980112 EW 199752 FS PS

TIEN COMPOSITE LIVING SKIN EQUIVALENTS.

TIDE ZUSAMMENGESETZTES AeQUIVALENT DER LEBENDEN HAUT.

TIFR EQUIVALENTS COMPOSITES DE PEAU VIVANTE.

IN EISENBERG, Mark, 6 Lord Howe Street, Dower Heights, NSW 2030, AU

PA EISENBERG, Mark, 6 Lord Howe Street, Dower Heights, NSW 2030, AU

SO Wila-EPS-1997-H52-T2

DS R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE

PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PI EP 526550 B1 19971229

OD 19930210

AI EP 1991-908747 19910424

PRAI AU 1990-9819 19900424

AU 1991-4302 19910122

RLI WO 91-AU160 910424 INTAKZ

WO 9116010 911031 INTPNR

REP EP 243132 A WO 86-02273 A

WO 88-08305 A AU 1374288 A

AU 1374388 A US 4485096 A

REN BELL. E. et al. (1983): "The Reconstruction of Living Skin, The Journal of Investigative Dermatology", Volume 81, No. 1, Supplement pages 2-10. (see pages 1 and 5 in particular) DYKES, P.J. et al. (1991): "In Vitro Reconstruction of Human Skin: The Use of Skin Equivalents as Potential Indicators of Cutaneous Toxicity, Toxicology In Vitro", Volume 5, No. 1, pages 1-8 (see introduction and discussion in particular) ROWLING, P.J.E. et al. (1990): "Fabrication and Reorganization of Dermal Equivalents Suitable for Skin Grafting after Major Cutaneous Injury, Biomaterials", Volume 11, pages 181-185; published April 1990

IC ICM A61F002-10
ICS A61L027-00 C12N005-08 C12N005-00

L3 ANSWER 5 OF 10 INPADOC COPYRIGHT 2000 EPO

LEVEL 1

AN 46467201 INPADOC EW 199807 UW 199807

TI BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT HF-COLL-18/514CF) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILATIONS

IN WOLF-GEORG FORSSMANN; MICHAEL SCHRADER; LUDGER STANDKER; MANFRED RAID; PETER SCHULZ-KNAPPE

INS FORSSMANN WOLF-GEORG; SCHRADER MICHAEL; STANDKER LUDGER; RAID MANFRED; SCHULZ-KNAPPE PETER

PA WOLF-GEORG FORSSMANN; HAEMOPEP PHARMA GMBH

PAS WOLF-GEORG FORSSMANN; HAEMOPEP PHARMA GMBH

DT Patent

PIT AUA1 COMP. SPEC. OPEN TO PUB. INSP.

PI AU 9727665 A1 19971112

AI AU 1997-27665 A 19970422

PRAI DE 1996-19615710 A 19960422

WO 1997-EP2012 W 19970422

L3 ANSWER 6 OF 10 USPATFULL

AN 96:112621 USPATFULL

TI Composite living skin equivalents

IN Eisenberg, Mark, 6 Lord Howe Street, Dover Heights, NSW 2030, Australia

PI US 35399 19961210
US 5282859 19940201 (Original)
WO 9116010 19911031

AI US 1994-346525 19941129 (8)
US 1991-777419 19911127 (Original)
WO 1991-AU160 19910424
19911127 PCT 371 date
19911127 PCT 102(e) date

PRAI AU 1990-9819 19900424
AU 1991-4302 19910122

DT Reissue

LN.CNT 652

INCL INCLM: 623/011.000
INCLS: 623/015.000; 623/066.000; 128/DIG.008; 435/240.240; 424/424.000; 602/042.000

NCL NCLM: 623/011.000
NCLS: 128/DIG.008; 424/424.000; 602/042.000; 623/015.000; 623/066.000

IC [6]
ICM: A61F002-02
ICS: A61F002-10; A61F002-00; C12N005-00

EXF 623/1; 623/2; 623/11; 623/12; 623/66; 435/240.24; 435/240.241; 424/424; 602/42; 128/DIG.8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 10 USPATFULL

AN 94:9198 USPATFULL

TI Composite living skin equivalents

IN Eisenberg, Mark, 6 Lord Howe Street, Dover Heights, NSW 2030, Australia

PI US 5282859 19940201
WO 9116010 19911031
AI US 1991-777419 19911127 (7)
WO 1991-AU160 19910424
19911127 PCT 371 date
19911127 PCT 102(e) date
PRAI AU 1990-9819 19900424
AU 1991-4302 19910122
DT Utility
LN.CNT 598
INCL INCLM: 623/011.000
INCLS: 623/015.000; 623/066.000; 128/DIG.008; 435/240.241; 424/424.000;
602/042.000
NCL NCLM: 623/011.000
NCLS: 128/DIG.008; 424/424.000; 435/371.000; 435/398.000; 602/042.000;
623/015.000; 623/066.000
IC [5]
ICM: A61F002-02
ICS: A61F002-10; A61F002-00; C12N005-00
EXF 623/11; 623/66; 623/15; 424/422; 424/423; 424/424; 128/DIG.8; 602/41;
602/42; 602/43; 602/48; 435/240.241; 435/283
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS
AN 1994:30378 CAPLUS
DN 120:30378
TI Collision-induced dissociation and charge-reversal processes of isomeric
C6H4X- (X = F, Cl and Br) anions
AU Tomperi, Paivi H.; Matimba, Henri E. K.; Ingemann, Steen; Nibbering, Nico
M. M.
CS Inst. Mass Spectrom., Univ. Amsterdam, Amsterdam, 1018 WS, Neth.
SO Rapid Commun. Mass Spectrom. (1993), 7(8), 749-56
CODEN: RCMSEF; ISSN: 0951-4198
DT Journal
LA English

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2000 ACS
AN 1980:573921 CAPLUS
DN 93:173921
TI Valence bond diatomics-in-molecules (DIM) treatment of collinear
interactions of Group IIA and IIB metal atoms with hydrogen halides:
application to the calcium hydrogen chloride system
AU Isaacson, Alan D.; Muckerman, James T.
CS Chem. Dep., Brookhaven Natl. Lab., Upton, NY, 11973, USA
SO J. Chem. Phys. (1980), 73(4), 1729-49
CODEN: JCPSA6; ISSN: 0021-9606
DT Journal
LA English

L3 ANSWER 10 OF 10 DGENE COPYRIGHT 2000 DERWENT INFORMATION LTD
AN 1997P-W44651 peptide DGENE
TI Protein HF-COLL-18/514cf - useful for treating, e.g. diseases of
supporting or connective tissue, respiratory or urogenital tract or of
the cardiovascular or nervous system
IN Forssmann W; Raida M; Schrader M; Schulz-knappe P
PA (EORS-I) FORSSMANN W
PI DE 19615710 AI 19971023 6p
AI DE 1996-19615710 19960422
PRAI DE 1996-19615710 19960422
DT Patent
LA German
OS 1997-514492 [48]

JPP/ent